WO2021205232A1 - Process for making antiinflammatory, antibacterial, antifungal and viricidal materials - Google Patents
Process for making antiinflammatory, antibacterial, antifungal and viricidal materials Download PDFInfo
- Publication number
- WO2021205232A1 WO2021205232A1 PCT/IB2021/000245 IB2021000245W WO2021205232A1 WO 2021205232 A1 WO2021205232 A1 WO 2021205232A1 IB 2021000245 W IB2021000245 W IB 2021000245W WO 2021205232 A1 WO2021205232 A1 WO 2021205232A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- metal
- deposition chamber
- matrix composite
- water
- depositing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C14/00—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
- C23C14/0021—Reactive sputtering or evaporation
- C23C14/0036—Reactive sputtering
- C23C14/0063—Reactive sputtering characterised by means for introducing or removing gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/30—Inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/082—Inorganic materials
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C14/00—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
- C23C14/0021—Reactive sputtering or evaporation
- C23C14/0036—Reactive sputtering
- C23C14/0042—Controlling partial pressure or flow rate of reactive or inert gases with feedback of measurements
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C14/00—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
- C23C14/06—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the coating material
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C14/00—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
- C23C14/06—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the coating material
- C23C14/08—Oxides
- C23C14/085—Oxides of iron group metals
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C14/00—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
- C23C14/06—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the coating material
- C23C14/14—Metallic material, boron or silicon
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C14/00—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
- C23C14/22—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the process of coating
- C23C14/34—Sputtering
- C23C14/35—Sputtering by application of a magnetic field, e.g. magnetron sputtering
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C14/00—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
- C23C14/58—After-treatment
- C23C14/5846—Reactive treatment
- C23C14/5853—Oxidation
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C30/00—Coating with metallic material characterised only by the composition of the metallic material, i.e. not characterised by the coating process
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00217—Wound bandages not adhering to the wound
- A61F2013/00221—Wound bandages not adhering to the wound biodegradable, non-irritating
- A61F2013/00225—Wound bandages not adhering to the wound biodegradable, non-irritating with non-degradable reinforcing layer, net or mesh
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00217—Wound bandages not adhering to the wound
- A61F2013/00234—Wound bandages not adhering to the wound metallic layer
Definitions
- the inert gas is present between about 92% to about 94%, the oxygen gas is present between about 3% to about 5% and the water vapor is present between about 2% to about 3% of the total composition of the one or more gases. In some embodiments, the inert gas is present at about 92.95%, the oxygen gas is present at about 4.25% and the water vapor is at about 2.8% of the total composition of the one or more gases.
- the liquid water is injected into the stream of the inert gas, by a syringe pump. In some embodiments, the liquid water is injected into the stream of inert gas, by the syringe pump at a flow rate between about 0.5 microliters per minute and about 11 microliters per minute.
- the liquid water is injected into the stream of the inert gas downstream of the inert gas mass flow controller, when the water is above 1.02 percent composition of the total composition.
- steam is injected directly into the deposition chamber.
- the inert gas mass flow controller controls the flow rate of the inert gas into the deposition chamber between about 100 SCCM and about 600 SCCM. In some embodiments, the inert gas mass flow controller controls the flow rate of the inert gas into the deposition chamber between about 350 SCCM and about 450 SCCM. In some embodiments, an oxygen gas mass flow controller controls the flow rate of the oxygen gas into the deposition chamber between about 0.1 SCCM and about 100 SCCM.
- the intergrain atoms of a metal, a metal oxide, oxygen, water and crystal grains of the metal wherein the crystal grains have a median size between about 2 nm and about 15 nm, wherein the intergrain atoms comprise about 50 to about 20 percent per unit surface area of the metal matrix composite material, and wherein the water comprises less than 4 percent by weight of the metal matrix composite material.
- the median size of the crystal grains is between about 2 nm and about 15 nm and intergrain atoms of the metal comprise between about 50 percent per unit surface area of the material to about 20 percent per unit surface area of the material.
- the molecular oxygen gas is selected from the group consisting of O2, 0 3 ,0 3 + ,0 2 + , 0 2 , Cb, O, 0 + , CT, ionized ozone, metastable excited oxygen, free electrons, H2O2 and OH.
- FIG. 6 A shows the effect of water added to an argon working gas on the antimicrobial activity of a metal matrix composite composed of an alloy of 35% silver and 65% gold deposited in Argon with no oxygen present at various flow rates of liquid water.
- FIG. 6B shows the effect of water added to an argon working gas on the antimicrobial activity of a metal matrix composite composed of an alloy of 35% silver and 65% gold deposited in various levels of oxygen with and without water.
- ophthalmology e.g. viral conjunctivitis, chronic eye infections and eye surgery
- general surgery e.g orthopedic surgery, surgical adhesions, laparoscopy and robotic surgery
- verruca e.g. heart, traumatic injury, transplants and infected implants.
- a metal matrix composite is composite material with at least two constituent parts, one being a metal necessarily, the other material may be a different metal or another material, such as a ceramic or organic compound. When at least three materials are present, it is called a hybrid composite. (https://en.wikipedia.org/wiki/Metal_matrix_composite).
- SCCM refers to standard cubic centimeters per minute.
- the one or more gases is an inert gas.
- the inert gas is argon.
- an inert gas mass flow controller controls the flow rate of the inert gas into the deposition chamber between about 100 SCCM and about 600 SCCM, where the active area of target is between about 100 cm 2 and 1000 cm 2 .
- the inert gas mass flow controller controls the flow rate of the inert gas into the deposition chamber between about 350 SCCM and about 450 SCCM, where the active area of target is between about 100 cm 2 and 1000 cm 2 .
- the one or more gases is an inert gas.
- the inert gas is argon.
- an inert gas mass flow controller controls the flow rate of the inert gas into the deposition chamber between about 100 SCCM and about 600 SCCM, where the active area of target is between about 250 cm 2 to about 300 cm 2 .
- the inert gas mass flow controller controls the flow rate of the inert gas into the deposition chamber between about 350 SCCM and about 450 SCCM, where the active area of target is between about 250 cm 2 to about 300 cm 2 .
- an oxygen gas mass flow controller controls the flow rate of the oxygen gas into the deposition chamber between about 0.1 SCCM and about 100 SCCM, where the active area of target is about 284 cm 2 . In some embodiments, an oxygen gas mass flow controller controls the flow rate of the oxygen gas into the deposition chamber between about 1 SCCM and about 20 SCCM, where the active area of target is about 284 cm 2 . In some embodiments, an oxygen gas mass flow controller controls the flow rate of the oxygen gas into the deposition chamber between about 5 SCCM and about 10 SCCM, where the active area of target is about 284 cm 2 . In some embodiments, an oxygen gas mass flow controller controls the flow rate of the oxygen gas into the deposition chamber at about 8 SCCM, where the active area of target is about 284 cm 2 .
- the method does not include a step of reducing internal pressure of the deposition chamber below about 1 x 10 8 torr within 24 hours, 12 hours, 6 hours, 3 hours prior to said depositing. In some embodiments, the method does not include a step of reducing internal pressure of the deposition chamber below about 1 x 10 7 torr within 24 hours, 12 hours, 6 hours, 3 hours prior to said depositing. In some embodiments, the method does not include a step of reducing internal pressure of the deposition chamber below about 1 x 10 6 torr within 24 hours, 12 hours, 6 hours, 3 hours prior to said depositing.
- the method does not include a step of reducing internal pressure of the deposition chamber below about 1 torr within 24 hours, 12 hours, 6 hours, 3 hours prior to said depositing. In some embodiments, the method does not include a step of reducing internal pressure of the deposition chamber below about lOtorr within 24 hours, 12 hours, 6 hours, 3 hours prior to said depositing. In some embodiments, the method does not include a step of reducing internal pressure of the deposition chamber below about 100 torr within 24 hours, 12 hours, 6 hours, 3 hours prior to said depositing. In some embodiments, the method does not include a step of reducing internal pressure of the deposition chamber below about 760 torr within 24 hours, 12 hours, 6 hours, 3 hours prior to said depositing.
- the method does not include a step of reducing internal pressure of the deposition chamber below atmospheric pressure within 24 hours, 12 hours, 6 hours, 3 hours prior to said depositing [0041] Described herein are methods for depositing metals.
- the metal is a noble metal.
- the noble metal is silver, gold, platinum, palladium, or a combination thereof.
- the method comprises depositing at least two metals on the substrate.
- the at least two metals comprise silver and gold.
- the at least two metals comprise silver and gold, wherein the silver is present at 65 percent and the gold is present at 35 percent.
- the at least two metals comprise silver and gold, wherein the silver is present at 35 percent and the gold is present at 65 percent.
- the internal pressure of the deposition chamber is about 1 millitorr to about 10 millitorr, about 1 millitorr to about 20 millitorr, about 1 millitorr to about 30 millitorr, about 1 millitorr to about 40 millitorr, about 1 millitorr to about 50 millitorr, about 1 millitorr to about 100 millitorr, about 10 millitorr to about 20 millitorr, about 10 millitorr to about 30 millitorr, about 10 millitorr to about 40 millitorr, about 10 millitorr to about 50 millitorr, about 10 millitorr to about 100 millitorr, about 20 millitorr to about 30 millitorr, about 20 millitorr to about 40 millitorr, about 20 millitorr to about 50 millitorr, about 20 millitorr to about 100 millitorr, about 30 millitorr to about 40 millitorr, about 30 millitorr to about 50 millitorr, about 30 millitorr to
- the substrate is a solid.
- the solid comprises metal foil, glass, or silicon.
- the substrate exhibits low outgassing.
- the substrate is an implant.
- the implant is a stent.
- the stent is a metal stent.
- the substrate comprises a polymer.
- the polymer is high- density polyethylene.
- the substrates comprise a mesh structure made from high density polyethylene.
- a dressing comprises the mesh structure made from high density polyethylene.
- a distance between a source and the substrate is between about 1 centimeter to about 20 centimeters.
- a distance between a source and the substrate is between about 1 centimeter to about 20 centimeters.
- the method of any one of embodiments 67-85, wherein the distance is between about 5 centimeters to about 15 centimeters.
- the method of any one of embodiments 67-86, wherein the distance is about 10 centimeters.
- 88. The method of any one of embodiments 67-87, wherein the method does not include a step of reducing internal pressure of the deposition chamber below about 10-7, 10-6, 10-5, 10-4, 10-3, 0.01, 0.1, 1, 10, 100, 760 Torr, or atmospheric pressure.
- the method further comprises depositing additional metals or metal oxides on the substrate.
- the one or more gases comprise an inert gas.
- the inert gas is Argon.
- the method of any one of embodiments 67-97, wherein the internal pressure of the deposition chamber during the depositing is maintained between about 5 millitorr and about 50 millitorr. 99.
- a method for preparing a metal matrix composite material comprising depositing one or more of a metal and a metal oxide on a substrate in a deposition chamber in the presence of a combination of one or more inert gases and oxygen gas, wherein the depositing of the at least one metal and metal oxide originates from a source, wherein the source is separated from the substrate by a distance of at least 5 centimeters.
- the method comprises, evacuating the chamber before said depositing.
- 125 The method of any one of embodiments 117-124, wherein the liquid water is injected into the stream of the inert gas, by a syringe pump.
- the method of any one of embodiments 117-142, wherein the noble metal is silver, gold, platinum, palladium, or a combination thereof. 144.
- the method of any one of embodiments 170-191, wherein the metal is a noble metal.
- the method of any one of embodiments 170-192, wherein the noble metal is silver, gold, platinum, palladium, or a combination thereof. 194.
- the method further comprises depositing additional metals or metal oxides on the substrate.
- the one or more gases comprise an inert gas. 200.
- the method of any one of embodiments 170-209, wherein the substrate comprises a polymer.
- the method of any one of embodiments 170-210, wherein the polymer is high-density polyethylene. 212.
- the metal matrix composite material of embodiment 220 comprising intergrain atoms of a metal, a metal oxide, oxygen, water and crystal grains of the metal, wherein the crystal grains have a median size between about 2 nm and about 15 nm, wherein the intergrain atoms comprise about 50 to about 20 percent per unit surface area of the metal matrix composite material, and wherein the oxygen comprises at least 2 percent by weight of the metal matrix composite material. 222.
- the metal matrix composite material embodiments 220 or 221, comprising intergrain atoms of a metal, a metal oxide, oxygen, water and crystal grains of the metal, wherein the crystal grains have a median size between about 2 nm and about 15 nm, wherein the intergrain atoms comprise about 50 to about 20 percent per unit surface area of the metal matrix composite material, and wherein the water comprises less than 4 percent by weight of the metal matrix composite material. 223.
- a metal matrix composite material comprising intergrain atoms of a metal, a metal oxide, oxygen, water and crystal grains of the metal having a median size between about 2 nm and about 15 nm, wherein the intergrain atoms comprise about 50 to about 20 percent per unit surface area of the metal matrix composite material
- the metal matrix composite material is made by a method comprising the steps of depositing one or more of a metal and a metal oxide on a substrate in a deposition chamber in the presence of water vapor and one or more gases, the one or more gases comprising oxygen gas, wherein the depositing of the at least one metal and metal oxide originates from a source, separated from the substrate by a distance of at least 5 centimeters, further wherein the method does not include a step of reducing internal pressure of the deposition chamber below about 10-7 torr within 24 hours, 12 hours, 6 hours, 3 hours prior to said depositing.
- the metal matrix composite material of embodiment 232, wherein the molecular oxygen gas comprises molecular oxygen gas in any form. 234.
- the metal matrix composite material of embodiment 233, wherein the molecular oxygen gas is selected from the group consisting of 02, 03,03+ 02+, 02-, 03, O, 0+, 0-, ionized ozone, metastable excited oxygen, free electrons, H202 and OH.
- Working gas composition Argon (80-99.9%), oxygen (0-20%) and water vapor.
- the water vapor is controlled by the water temperature, from 20C, in the argon flow line which controls the vapor pressure of the water and allows more or less to be entrained in the working as is required.
- Target 99.99% silver
- Target dimensions 20.25” X 5” X 0.25”
- the antimicrobial effect of the coating was tested using a log reduction test.
- the bacterial inoculum was generated in calf serum at 37°C by inoculating 50 mL of calf serum with a 16-hour old culture of P. aeruginosa and incubated for 16h. This produced a 1.05 X 10 9 CFU inoculum.
- Dressings were prepared from two silver coated pieces of HDPE (2.5 X 2.5cm) with a piece (2.5 X 2.5cm) of cotton gauze in between. The dressings were placed on a sterile piece of plastic (3.2 X 3.2 cm) in the inverted lid of a Petri dish in a Class 2 Laminar Flow hood.
- the CFU/mL was then converted to a log number.
- the log reduction was calculated by subtracting the log of the recovered CFU from the log of the inoculum. A log reduction greater than 3 is considered bactericidal.
- the dressings made with 35ul/min water contained a total Ag of 1012ug/square inch; Ammonium hydroxide Soluble Ag of 220ug/square inch which equated to 22% ammonium hydroxide soluble silver.
- the P. aeruginosa log reduction was ⁇ 2 indicating that the silver coating deposited in a wet environment was not bactericidal in calf serum.
- the dressings made with 0% O2 and 6ul/min water contained a total Ag of 4160ug/square inch; Ammonium hydroxide Soluble Ag of 150ug/square inch which equated to 2.4% ammonium hydroxide soluble silver.
- the P. aeruginosa log reduction was 2. lindicating that the silver coating deposited in a wet environment was not bactericidal in calf serum
- the dressings made with 0% O2 and 4ul/min water contained a total Ag of 4800ug/square inch; Ammonium hydroxide Soluble Ag of 102ug/square inch which equated to 2.1% ammonium hydroxide soluble silver.
- the P. aeruginosa log reduction was 2.1 indicating that the silver coating deposited in a wet environment was not bactericidal in calf serum
- the CFU/mL was then converted to a log number.
- the log reduction was calculated by subtracting the log of the recovered CFU from the log of the inoculum. A log reduction greater than 3 is considered bactericidal.
- the dressings made with 0% O2 and 9ul/min water contained a total Ag of
- aeruginosa log reduction was ⁇ 2 indicating that the silver coating deposited in a wet environment was not bactericidal in calf serum
- the dressings made with 0% O2 and 33ul/min water contained a total Ag of 4800ug/square inch; Ammonium hydroxide Soluble Ag of 102ug/square inch which equated to 8% ammonium hydroxide soluble silver.
- the P. aeruginosa log reduction was ⁇ 2 indicating that the silver coating deposited in a wet environment was not bactericidal in calf serum [0139] Simply sputtering in a mixture of Argon and water does not result in the production of high levels of ammonium hydroxide soluble silver or antimicrobial activity.
- Example 6 The effect of water (l-9ul/min) and argon on the level of ammonium hydroxide soluble silver
- the dressings made with 2% O2 and 5ul/min water contained a total Ag of 5664ug/square inch; Ammonium hydroxide Soluble Ag of 1270ug/square inch which equated to 22% ammonium hydroxide soluble silver.
- The/ 1 aeruginosa log reduction was >7 indicating that the silver coating deposited in a wet environment was bactericidal in calf serum.
- the water was injected into the Ar stream at flow rates of 0 or 9 uL/min.
- the stainless-steel piping was heated to 50oC between the injection port and the MFC to maintain the water in a gaseous state.
- the sputtering power was 570 Watts (1.5 Amps at 380 Volts), the flow rate for Argon/0 2 was 396/4, 392/8, 388/12 and 384/16 SCCM, with a working gas pressure of 40 mTorr.
- the target to substrate distance was 10cm.
- the target was rectangular and measured 12.7 cm X 51.4 cm.
- the target was cooled and maintained at 15°C using a chiller.
- the runs were 30 minutes long and the HDPE mesh was moving at 15cm/min.
- the antimicrobial effect of the coating was tested using a log reduction test.
- the bacterial inoculum was generated in calf serum at 37°C by inoculating 50mL of calf serum with a 16-hour old culture of P. aeruginosa and incubated for 16h. This produced a 1.05 X 10 9 CFU inoculum.
- Dressings were prepared from two silver coated pieces of HDPE (2.5 X 2.5cm) with a piece (2.5 X 2.5cm) of cotton gauze in between. The dressings were placed on a sterile piece of plastic (3.2 X 3.2 cm) in the inverted lid of a Petri dish in a Class 2 Laminar Flow hood.
- ID is the initial dilution
- SD are subsequent dilutions
- FD is the final dilution
- 50 converts to mL
- CFU is the colony forming units counted at the dilution used for the calculation.
- the CFU/mL was then converted to a log number.
- the log reduction was calculated by subtracting the log of the recovered CFU from the log of the inoculum. A log reduction greater than 3 is considered bactericidal.
- the dressings made with 0% O2 and 2ul/min water had a log reduction of 1.0 on P. aeruginosa indicating that the silver/gold coating deposited in a wet environment was not bactericidal in calf serum.
- inoculum 200uL of inoculum were applied to the dressings in a Petri dish which were then covered with a second piece of plastic (3.2 X 3.2 cm) and incubated for one hour at 37°C.
- the dressings, including the plastic base and cover pieces, with the bacteria were then placed in 1.8 mL of sodium thioglycolate saline (STS) to inactivate the silver, then further diluted using peptone water, and plated on Mueller-Hinton agar. Plates are checked after 24 h of incubation and the total bacterial colonies forming units were calculated.
- STS sodium thioglycolate saline
- TABLE 2 summarizes assay effects in log reduction of P. aeruginosa relative to various target to substrate distances.
- This example was included to demonstrate an anti-inflammatory coating formed by DC magnetron sputtering on a commercial high-density polyethylene (HDPE) mesh when the water is injected into the Ar upstream of the MFC via a syringe pump prior to entering the deposition chamber.
- the mesh was coated by DC magnetron sputtering 99.99% pure silver, 65% Ag/35% Au or 20% Ag/80% Au on the surface using the following conditions.
- the working gases used were high purity commercial Ar and O2 (95.75/4.25 wt % final concentration) which were added to the vacuum chamber through separate mass flow controllers.
- the water was injected into the Ar stream at a flow rate of 9 uL/min.
- the stainless- steel piping was heated to 50°C between the injection port and the MFC to maintain the water in a gaseous state.
- the sputtering power was 1.8 Amps
- the flow rate for Argon was 383 SCCM
- for O2 was 17 SCCM, with a working gas pressure of 40 mTorr.
- the target to substrate distance was 10cm.
- the target was rectangular and measured 12.7 cm X 51.4 cm.
- the target was cooled and maintained at 15°C using a chiller.
- the runs were 6 hours long and the HDPE mesh was moving at 0.69 in/min.
- Each treated pig shall have approximately 3 mL of 10% v/v 1,2-dinitrochlorobenzene (DNCB) in 4:1 acetone-olive oil painted over the shaved area of about 25 cm c 15 cm, which is caudal to the scapula running over the rib cage and 5 cm off the dorsal median line (representing ⁇ 5% of the total body surface area).
- DNCB 1,2-dinitrochlorobenzene
- the stainless-steel piping was heated to 50°C between the injection port and the MFC to maintain the water in a gaseous state.
- the sputtering power was 1.8 Amps
- the flow rate for Argon was 383 SCCM
- for 02 was 17 SCCM, with a working gas pressure of 40 mTorr.
- the target to substrate distance was 10cm.
- the target was rectangular and measured 12.7 cm X 51.4 cm.
- the target was cooled and maintained at 15°C using a chiller.
- the runs are 6 hours long and the HDPE meshwas moving at 0.69 in/min.
- This example is included to demonstrate an antimicrobial coating formed by DC magnetron sputtering on a commercial high-density polyethylene (HDPE) mesh when the waterwas injected into the Ar upstream of the MFC via a syringe pump prior to entering the deposition chamber.
- the mesh was coated by DC magnetron sputtering 99.99% pure silver, on the surface using the following conditions.
- the working gases used were high purity commercial Ar and O2 (95.75/4.25 wt % final concentration) which were added to the vacuum chamber through separate mass flow controllers.
- the water was injected into the Ar stream at a flow rate of 9 uL/min.
- a silver-based metal matrix composite material produced by methods described herein, when exposed to a CO2 containing environment, comprises crystalline silver carbonate Ag 2 C0 3 (s). This is confirmed by X-ray diffraction comparison to other nanocrystalline materials.
- a commercially available nanocrystalline material, Acticoat was characterized by x-ray diffraction as shown in FIG 8A. The material did not display a spectral peak indicative of silver carbonate.
- a silver- based metal matrix composite material produced by methods as described herein did display an x-ray diffraction spectral peak, confirming silver carbonate as seen in FIGS. 8BC.
- FIG 8A shows x-ray diffraction spectra of a sample that was exposed to atmosphere, where CO2 is present at 400 ppm, after the depositing and before X-ray diffraction for a period of no longer than tens of minutes.
- water was injected upstream of the mass flow controller at 50 °C, power was set at 1.8 A at 380 V, and the water flow rate was 20uL water/min.
- Target active area, or etch track area, was measured to be 284.39 cm 2 .
- the sample was determined to have 70% ammonia soluble.
- a prominent x-ray diffraction spectral peak, confirming sliver carbonate is observed at 32.8 degrees as shown in FIG. 8B.
- a second sample was synthesized in a process as described herein utilizing a microvalve upstream of the mass flow controller to inject water at 33uL water/min, oxygen gas was present at 2% of the total working gas composition and sputtering power was set at 1.5 A at 380 V.
- Target active area, or etch track area was measured to be 284.39 cm 2 .
- FIG. 8C shows two peaks, one at 32.2 confirming silver oxide and one peak at 32.8 confirming silver carbonate. The presence of silver carbonate in the material prepared by methods described herein, upon exposure to a CO2 environment, as compared to the commercially available silver nanocrystalline material infers a difference in structure.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Metallurgy (AREA)
- Mechanical Engineering (AREA)
- Materials Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Fluid Mechanics (AREA)
- Physics & Mathematics (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Physical Vapour Deposition (AREA)
- Materials For Medical Uses (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023503518A JP7874609B2 (ja) | 2020-04-06 | 2021-04-05 | 抗炎症性、抗菌性、抗真菌性、および殺菌性の材料を製造するためのプロセス |
| CN202180040814.6A CN115777028A (zh) | 2020-04-06 | 2021-04-05 | 用于制备抗炎、抗细菌、抗真菌和杀病毒材料的方法 |
| KR1020227038451A KR20230021641A (ko) | 2020-04-06 | 2021-04-05 | 항염증, 항세균, 항진균 및 살바이러스 재료의 제조 방법 |
| EP21784162.6A EP4133119A4 (en) | 2020-04-06 | 2021-04-05 | PROCESS FOR THE PRODUCTION OF ANTI-INFLAMMATORY, ANTIBACTERIAL, FUNGICIDAL AND VIRICIDIAL MATERIALS |
| MX2022012517A MX2022012517A (es) | 2020-04-06 | 2021-04-05 | Proceso para fabricar materiales antiinflamatorios, antibacterianos, antifungicos y viricidas. |
| BR112022020155A BR112022020155A2 (pt) | 2020-04-06 | 2021-04-05 | Processo para fabricação de materiais anti-inflamatórios, antibacterianos, antifúngicos e viricidas |
| IL297110A IL297110B2 (en) | 2020-04-06 | 2021-04-05 | Process for preparing anti-degradative, antibacterial, fungicidal and antiviral agents |
| AU2021252195A AU2021252195A1 (en) | 2020-04-06 | 2021-04-05 | Process for making antiinflammatory, antibacterial, antifungal and viricidal materials |
| CA3179404A CA3179404A1 (en) | 2020-04-06 | 2021-04-05 | Process for making antiinflammatory, antibacterial, antifungal and viricidal materials |
| US17/937,747 US12472102B2 (en) | 2020-04-06 | 2022-10-03 | Process for making antiinflammatory, antibacterial, antifungal and viricidal materials |
| US19/356,785 US20260157890A1 (en) | 2020-04-06 | 2025-10-13 | Process for making antiinflammatory, antibacterial, antifungal and viricidal materials |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063006044P | 2020-04-06 | 2020-04-06 | |
| US63/006,044 | 2020-04-06 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/937,747 Continuation US12472102B2 (en) | 2020-04-06 | 2022-10-03 | Process for making antiinflammatory, antibacterial, antifungal and viricidal materials |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021205232A1 true WO2021205232A1 (en) | 2021-10-14 |
Family
ID=78023095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2021/000245 Ceased WO2021205232A1 (en) | 2020-04-06 | 2021-04-05 | Process for making antiinflammatory, antibacterial, antifungal and viricidal materials |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12472102B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4133119A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7874609B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230021641A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115777028A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021252195A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022020155A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3179404A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL297110B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022012517A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021205232A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12472102B2 (en) | 2020-04-06 | 2025-11-18 | Kheprion, Inc. | Process for making antiinflammatory, antibacterial, antifungal and viricidal materials |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI910500B (zh) * | 2023-11-28 | 2026-01-01 | 何文琮 | 產氣貼片 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2134217A1 (en) * | 1992-05-19 | 1993-10-25 | Robert Edward Burrell | Anti-Microbial Coating for Medical Devices |
| CA2136454A1 (en) * | 1993-11-18 | 1995-05-19 | Robert Edward Burrell | Process of Activating Anti-Microbial Materials |
| US5837275A (en) * | 1992-05-19 | 1998-11-17 | Westaim Technologies, Inc. | Anti-microbial materials |
| CA2428922A1 (en) * | 2003-05-16 | 2004-11-16 | Exciton Technologies Inc. | Processes for production of articles coated with oxidized silver species used as antimicrobial materials for medical devices |
| CA2572598A1 (en) * | 2006-01-05 | 2007-07-05 | Howmedica Osteonics Corp. | Method for fabricating a medical implant component and such component |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5372660A (en) * | 1993-08-26 | 1994-12-13 | Smith & Nephew Richards, Inc. | Surface and near surface hardened medical implants |
| CA2136455C (en) * | 1993-11-18 | 1999-06-29 | Robert Edward Burrell | Process for producing anti-microbial effect with complex silver ions |
| CA2635062C (en) * | 2002-12-18 | 2010-10-26 | Chameleon Scientific Corporation | Antimicrobial coating methods |
| CA2460585A1 (en) | 2003-05-16 | 2004-11-16 | Exciton Technologies Inc. | Deposition products, composite materials and processes for the production thereof |
| ATE510455T1 (de) * | 2007-10-03 | 2011-06-15 | 3M Innovative Properties Co | Verfahren zur limitierung des mikroorganismenwachstums |
| EP3291848A1 (en) * | 2015-05-05 | 2018-03-14 | 3M Innovative Properties Company | Anti-microbial articles and methods of using same |
| WO2021205232A1 (en) | 2020-04-06 | 2021-10-14 | Burrell Robert E | Process for making antiinflammatory, antibacterial, antifungal and viricidal materials |
-
2021
- 2021-04-05 WO PCT/IB2021/000245 patent/WO2021205232A1/en not_active Ceased
- 2021-04-05 IL IL297110A patent/IL297110B2/en unknown
- 2021-04-05 AU AU2021252195A patent/AU2021252195A1/en active Pending
- 2021-04-05 KR KR1020227038451A patent/KR20230021641A/ko active Pending
- 2021-04-05 JP JP2023503518A patent/JP7874609B2/ja active Active
- 2021-04-05 MX MX2022012517A patent/MX2022012517A/es unknown
- 2021-04-05 CA CA3179404A patent/CA3179404A1/en active Pending
- 2021-04-05 BR BR112022020155A patent/BR112022020155A2/pt unknown
- 2021-04-05 CN CN202180040814.6A patent/CN115777028A/zh active Pending
- 2021-04-05 EP EP21784162.6A patent/EP4133119A4/en active Pending
-
2022
- 2022-10-03 US US17/937,747 patent/US12472102B2/en active Active
-
2025
- 2025-10-13 US US19/356,785 patent/US20260157890A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2134217A1 (en) * | 1992-05-19 | 1993-10-25 | Robert Edward Burrell | Anti-Microbial Coating for Medical Devices |
| US5837275A (en) * | 1992-05-19 | 1998-11-17 | Westaim Technologies, Inc. | Anti-microbial materials |
| CA2136454A1 (en) * | 1993-11-18 | 1995-05-19 | Robert Edward Burrell | Process of Activating Anti-Microbial Materials |
| CA2428922A1 (en) * | 2003-05-16 | 2004-11-16 | Exciton Technologies Inc. | Processes for production of articles coated with oxidized silver species used as antimicrobial materials for medical devices |
| CA2572598A1 (en) * | 2006-01-05 | 2007-07-05 | Howmedica Osteonics Corp. | Method for fabricating a medical implant component and such component |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP4133119A4 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12472102B2 (en) | 2020-04-06 | 2025-11-18 | Kheprion, Inc. | Process for making antiinflammatory, antibacterial, antifungal and viricidal materials |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230021641A (ko) | 2023-02-14 |
| AU2021252195A1 (en) | 2022-12-08 |
| JP7874609B2 (ja) | 2026-06-16 |
| IL297110B2 (en) | 2026-04-01 |
| CN115777028A (zh) | 2023-03-10 |
| IL297110A (en) | 2022-12-01 |
| US20230172759A1 (en) | 2023-06-08 |
| BR112022020155A2 (pt) | 2023-03-07 |
| US20260157890A1 (en) | 2026-06-11 |
| EP4133119A4 (en) | 2024-07-17 |
| JP2023520740A (ja) | 2023-05-18 |
| EP4133119A1 (en) | 2023-02-15 |
| US12472102B2 (en) | 2025-11-18 |
| CA3179404A1 (en) | 2021-10-14 |
| IL297110B1 (en) | 2025-12-01 |
| MX2022012517A (es) | 2023-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bonilla-Gameros et al. | Silver-based antibacterial strategies for healthcare-associated infections: Processes, challenges, and regulations. An integrated review | |
| US20050003019A1 (en) | Ionic plasma deposition of anti-microbial surfaces and the anti-microbial surfaces resulting therefrom | |
| Kuzminova et al. | Antibacterial nanocomposite coatings produced by means of gas aggregation source of silver nanoparticles | |
| Chen et al. | Improved immunoregulation of ultra-low-dose silver nanoparticle-loaded TiO2 nanotubes via M2 macrophage polarization by regulating GLUT1 and autophagy | |
| US12472102B2 (en) | Process for making antiinflammatory, antibacterial, antifungal and viricidal materials | |
| US6365220B1 (en) | Process for production of actively sterile surfaces | |
| EP0564503B1 (en) | Actively sterile surfaces | |
| Ferreri et al. | Silver activation on thin films of Ag–ZrCN coatings for antimicrobial activity | |
| Rtimi et al. | ZrNO–Ag co-sputtered surfaces leading to E. coli inactivation under actinic light: Evidence for the oligodynamic effect | |
| Rtimi et al. | Comparison of HIPIMS sputtered Ag-and Cu-surfaces leading to accelerated bacterial inactivation in the dark | |
| HU217644B (hu) | Módosított fémanyagok, eljárás azok előállítására és a velük bevont orvosi eszközök | |
| Siegel et al. | Properties of silver nanostructure-coated PTFE and its biocompatibility | |
| MX2008009511A (es) | Metodos de recubrimiento anti-microbiano. | |
| EP2741792A1 (en) | Process for the production by plasma of nanometric thickness coatings allowing controlled release of silver ions of other elements, or of molecules of biomedical interest, from solid products, and products thus coated | |
| CN107815665A (zh) | 一种二氧化钛薄膜及其制备方法和应用 | |
| CN102886926A (zh) | 抗菌镀膜件及其制备方法 | |
| RU2167526C2 (ru) | Антимикробные материалы | |
| Ozeki et al. | Photocatalytic hydroxyapatite/titanium dioxide multilayer thin film deposited onto glass using an rf magnetron sputtering technique | |
| CN110144561A (zh) | 一种持久耐用具有抗菌功能的硬质涂层的制备方法 | |
| CN108348632B (zh) | 抗微生物制品及其使用方法 | |
| CN102580149A (zh) | 一种抗菌涂层及其制备方法 | |
| Gnanasekar et al. | Impact of atmospheric pressure nonthermal plasma on Curcumin-Loaded Polyvinyl Alcohol/Chitosan polymer films for controlled drug release application | |
| Tang et al. | A study on antibacterial properties of Ag+-implanted pyrolytic carbon | |
| UA46720C2 (uk) | Спосіб одержання антимікробного матеріалу, спосіб досягнення антимікробного ефекту, антимікробна форма срібного матеріалу, тонкозернистий антимікробний матеріал та спосіб одержання тонкозернистого антимікробного матеріалу | |
| Jeong et al. | Fabrication of cobalt-organic composite thin film via plasma-enhanced chemical vapor deposition for antibacterial applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21784162 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 3179404 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 2023503518 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2021784162 Country of ref document: EP Effective date: 20221107 |
|
| ENP | Entry into the national phase |
Ref document number: 2021252195 Country of ref document: AU Date of ref document: 20210405 Kind code of ref document: A |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022020155 Country of ref document: BR |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112022020155 Country of ref document: BR Free format text: APRESENTE, NO PRAZO DE 60 (SESSENTA) DIAS, RELATORIO DESCRITIVO E DESENHOS COM O TEXTO TRADUZIDO PARA O PORTUGUES. |
|
| ENP | Entry into the national phase |
Ref document number: 112022020155 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221005 |
|
| WWG | Wipo information: grant in national office |
Ref document number: 297110 Country of ref document: IL |